193 related articles for article (PubMed ID: 17292735)
21. Treating imatinib resistance in the few in CML-A key step towards cure in all.
Giles FJ
Leuk Res; 2010 Sep; 34(9):1123-4. PubMed ID: 20417556
[No Abstract] [Full Text] [Related]
22. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
23. [Results of clinical studies on a selective inhibitor of ABL tyrosine kinase (STI571) in patients with Ph(+) leukemia].
Ohnisi K
Rinsho Ketsueki; 2002 Apr; 43(4):235-8. PubMed ID: 12043198
[No Abstract] [Full Text] [Related]
24. [Current status and future perspectives of the Glivec Registration System established by JSCH/JSH-TARGET].
Kizaki M;
Rinsho Ketsueki; 2007 Jun; 48(6):468-74. PubMed ID: 17633094
[No Abstract] [Full Text] [Related]
25. [Treatment strategies for chronic myeloid leukemia].
Jinnai I
Rinsho Ketsueki; 2005 Jan; 46(1):1-6. PubMed ID: 16708910
[No Abstract] [Full Text] [Related]
26. [Gleevec: an novel inhibitor of bcr-abl tyrosine kinase].
Guo XN; Ding J
Sheng Li Ke Xue Jin Zhan; 2003 Apr; 34(2):183-6. PubMed ID: 12889162
[No Abstract] [Full Text] [Related]
27. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
28. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
29. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
Rodrigues MS; Sattler M
J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
[No Abstract] [Full Text] [Related]
30. Imatinib results in better quality of life for CML patients than interferon/Ara-C.
J Support Oncol; 2003; 1(1):77. PubMed ID: 15352651
[No Abstract] [Full Text] [Related]
31. Revised advice on use of imatinib for chronic myeloid leukaemia.
Campbell K
Nurs Times; 2003 Oct 14-20; 99(41):20-1. PubMed ID: 14603651
[TBL] [Abstract][Full Text] [Related]
32. Hope for leukemia.
Lichtman MA
Health News; 2001 Jan; 7(1):3. PubMed ID: 11198409
[No Abstract] [Full Text] [Related]
33. [The 2nd generation of TKIs for chronic myeloid leukemia].
Matsumura I
Rinsho Ketsueki; 2010 Oct; 51(10):1386-94. PubMed ID: 20962471
[No Abstract] [Full Text] [Related]
34. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
Arancibia AM; Bendit I; Epelman S
Pediatr Blood Cancer; 2008 May; 50(5):1078. PubMed ID: 18085674
[No Abstract] [Full Text] [Related]
35. Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: rapid response to imatinib mesylate (STI571).
Imashuku S; Morimoto A; Kuriyama K; Kano G; Hibi S; Todo S
Med Pediatr Oncol; 2003 Aug; 41(2):159-60. PubMed ID: 12825226
[No Abstract] [Full Text] [Related]
36. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
[No Abstract] [Full Text] [Related]
37. New leukemia drug shows promise against Gleevec resistance.
Ashraf H
Drug Discov Today; 2005 Apr; 10(7):453-4. PubMed ID: 15809187
[No Abstract] [Full Text] [Related]
38. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
39. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
40. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment.
Kawakami Y; Nakamura K; Nishibu A; Yanagihori H; Kimura H; Yamamoto T
Acta Derm Venereol; 2008; 88(2):185-6. PubMed ID: 18311459
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
